Redefining Therapeutic Boundaries: PD-1 Blockade Facilitates Surgical Cure in EGFR-TKI Refractory EGFR-Mutant NSCLC with Pleural Metastases
{{output}}
We present a 57-year-old female diagnosed with stage cT3N1M1a (IVA) EGFR L858R-mutant lung adenocarcinoma (PD-L1 TPS 60%). The patient attained sustained disease control with a partial response lasting 22 months on first-line gefitinib. Following progression w... ...
